TY - JOUR
T1 - Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy
AU - Saini, Kamal S.
AU - Lanza, Carlo
AU - Romano, Marco
AU - de Azambuja, Evandro
AU - Cortes, Javier
AU - de las Heras, Begoña
AU - de Castro, Javier
AU - Lamba Saini, Monika
AU - Loibl, Sibylle
AU - Curigliano, Giuseppe
AU - Twelves, Chris
AU - Leone, Manuela
AU - Patnaik, Mrinal M.
N1 - Funding Information:
Competing interests K.S.S. reports consulting fees from the European Commission outside the submitted work. C.L. reports consulting fees from Anaveon AG, Akebia Therapeutics Inc, and Ergomed Plc outside the submitted work. E.d.A. reports honoraria and advisory board from Roche/GNE, Novartis, and Seattle Genetics; travel grants from Roche/GNE GSK and Novartis; and research grant to institution from Roche/GNE, AstraZeneca, GSK, Novartis, and Servier outside the submitted work. J.C. reports consulting/advisory fees from Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Servier, Merck Sharp&Dohme, GSK, Leuko, Bioasis, Clovis Oncology, and Boehringer Ingelheim; honoraria from Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp&Dohme, and Daiichi Sankyo; research funding to his institution from Roche, Ariad, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer Healthcare, Eisai, F.Hoffman-La Roche, Guardanth Health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Puma C, and Queen Mary University of London; stock, patents, and intellectual property from MedSIR; travel, accommodation and expenses from Roche, Novartis, Eisai, Pfizer, and Daiichi Sankyo outside the submitted work. G.C. reports personal fees for consulting, advisory role, and speakers’ bureau from Roche/Genentech, Novartis, Pfizer, Lilly, Foundation Medicine, Samsung, and Daichii-Sankyo; honoraria from Ellipses Pharma; fees for travel and accommodation from Roche/Genentech and Pfizer outside the submitted work. Other authors do not report any competing interests.
Publisher Copyright:
© 2020, Cancer Research UK.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19.
AB - Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85086774432&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086774432&partnerID=8YFLogxK
U2 - 10.1038/s41416-020-0948-x
DO - 10.1038/s41416-020-0948-x
M3 - Comment/debate
C2 - 32572174
AN - SCOPUS:85086774432
VL - 123
SP - 694
EP - 697
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 5
ER -